prikaz prve stranice dokumenta What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research
  Preuzmi
PDF 544.64 KB
Znanstveni rad - Izvorni znanstveni rad
What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research
Journal of Neural Transmission, 120 (2013), 1; 233-252. https://doi.org/10.1007/s00702-012-0877-9
Šalković-Petrišić, Melita; Knezović, Ana; Hoyer, Siegfried; Riederer, Peter

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Šalković Petrišić, M., Knezović, A., Hoyer, S. i Riederer, P. (2013). What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research. Journal of Neural Transmission, 120. (1), 233-252. doi: 10.1007/s00702-012-0877-9

Šalković Petrišić, Melita, et al. "What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research." Journal of Neural Transmission, vol. 120, br. 1, 2013, str. 233-252. https://doi.org/10.1007/s00702-012-0877-9

Šalković Petrišić, Melita, Ana Knezović, Siegfried Hoyer i Peter Riederer. "What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research." Journal of Neural Transmission 120, br. 1 (2013): 233-252. https://doi.org/10.1007/s00702-012-0877-9

Šalković Petrišić, M., et al. (2013) 'What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research', Journal of Neural Transmission, 120(1), str. 233-252. doi: 10.1007/s00702-012-0877-9

Šalković Petrišić M, Knezović A, Hoyer S, Riederer P. What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research. Journal of Neural Transmission [Internet]. 01.2013. [pristupljeno 14.05.2024.];120(1):233-252. doi: 10.1007/s00702-012-0877-9

M. Šalković Petrišić, A. Knezović, S. Hoyer i P. Riederer, "What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research", Journal of Neural Transmission, vol. 120, br. 1, str. 233-252, Siječanj 2013. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:642117. [Citirano: 14.05.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:642117
Podaci o radu
Naslov (engleski)What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research
AutorMelita Šalković-Petrišić
AutorAna Knezović
AutorSiegfried Hoyer
AutorPeter Riederer
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Sažetak (engleski)
Experimental models that faithfully mimic the developmental pathology of sporadic Alzheimer's disease (sAD) in humans are important for testing the novel therapeutic approaches in sAD treatment. Widely used transgenic mice AD models have provided valuable insights into the molecular mechanisms underlying the memory decline but, due to the particular β-amyloid-related gene manipulation, they resemble the familial but not the sporadic AD form, and are, therefore, inappropriate for this purpose. In line with the recent findings of sAD being recognised as an insulin resistant brains state (IRBS), a new, non-transgenic, animal model has been proposed as a representative model of sAD, developed by intracerebroventricular application of the betacytotoxic drug streptozotocin (STZ-icv). The STZ-icv-treated animals (mostly rats and mice) develop IRBS associated with memory impairment and progressive cholinergic deficits, glucose hypometabolism, oxidative stress and neurodegeneration that share many features in common with sAD in humans. The therapeutic strategies (acetylcholinesterase inhibitors, antioxidants and many other drugs) that have been tested until now on the STZ-icv animal model have been reviewed and the comparability of the drugs' efficacy in this non-transgenic sAD model and the results from clinical trials on sAD patients, evaluated.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeZavršna verzija rukopisa prihvaćena za objavljivanje (postprint)
Naslov časopisaJournal of Neural Transmission
Brojčani podacivol. 120, br. 1, str. 233-252
p-ISSN0300-9564
DOIhttps://doi.org/10.1007/s00702-012-0877-9
URN:NBNurn:nbn:hr:105:642117
Datum objave publikacije2013-01
URL dokumentahttps://doi.org/10.1007/s00702-012-0877-9
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-27 19:35:34